Research Topics
Species | K RezvaniSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignanciesKatayoun Rezvani
Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
Blood 111:236-42. 2008..01). This is the first demonstration that a combined PR1 and WT1 vaccine is immunogenic. These results support further studies of combination immunization strategies in leukemia patients...- Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemiaKatayoun Rezvani
Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
Blood 110:1924-32. 2007..Our results support the immunogenicity of WT1 after SCT for ALL and highlight the potential for WT1 vaccines to boost GVL after SCT for ALL... 
Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activityK Rezvani
Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Cytotherapy 9:245-51. 2007..However, little is known about the nature, origin and kinetics of the anti-leukemic T-cell responses involved...- High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCTKatayoun Rezvani
Stem Cell Allogeneic Transplant Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
Blood 108:1291-7. 2006..Our findings suggest that graft T(reg) content may predict for risk of GVHD after SCT. Determining the T(reg) levels in the donor and manipulating T(reg)s early after transplantation may provide a new approach to controlling GVHD... - T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterizationKatayoun Rezvani
Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung Blood Institute and Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 11:8799-807. 2005..Four HLA-A*0201-restricted WT1-derived epitopes have been identified: WT37, WT126, WT187, and WT235. We determined the natural immunogenecity of these antigens in patients with hematologic malignancies and healthy donor... - Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 proteinA S M Yong
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
Leukemia 25:629-37. 2011..A higher BMI-1 expression in CML CD34(+) progenitors was associated with native BMI-1 immune responses. These immune responses to PcG proteins may target leukemia stem cells and have relevance for disease control by GVL... - Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapyA S M Yong
Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, M20892 1202, USA
Leukemia 22:1721-7. 2008.... - Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantationKatayoun Rezvani
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
Blood 102:2892-900. 2003..The increased response in patients after SCT suggests a quantitative explanation for the greater effect of allogeneic SCT... - Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemiaB N Savani
Stem Cell Transplantation Section, Hematology Branch, National Institutes of Health, Bethesda, MD 20892 1202, USA
Leukemia 21:2145-52. 2007..7, P=0.028) and improved survival (HR 11.4, P=0.03). Results suggest that T cell-depleted SCT might be improved and the GVL effect enhanced by selecting donors with favorable KIR genotype, and by optimizing CD34 and CD3 doses... - Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignanciesMatthias Grube
Hematology Branch, National Heart-Lung-Blood Institute/NIH, 9000 Rockville Pike, Building 10, Bethesda, MD 20892, USA
Clin Cancer Res 10:1047-56. 2004..They are of low avidity and require high doses of peptide for activation. Strategies to increase T-cell avidity would be necessary for T-cell immunotherapeutic approaches using the peptides studied... - T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcomeAldemar Montero
Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland 20892-1202, USA
Biol Blood Marrow Transplant 12:1318-25. 2006..However, this chronic GVHD after T cell add back is associated with less mortality and retains a protective effect in terms of relapse, at least in the standard-risk patients... - Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemiaBipin N Savani
Stem Cell Allogeneic Transplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bldg 10, Hatfield CRC, Bethesda, MD 20892-1202, USA
Blood 107:1688-95. 2006..These results suggest that transplanted CD34 cell doses greater than 5 x 10(6)/kg may improve outcomes by increasing the early recovery of NK cells... 
The role of the immune system in myelodysplasia: implications for therapyElaine M Sloand
National Heart Lung and Blood Institute, Hematology Branch, Bethesda, MD 20892, USA
Semin Hematol 45:39-48. 2008..Here, we review the evidence supporting a role of the immune system in the pathophysiology of MDS and the results of clinical trials of immunosuppressive agents...- Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host diseaseStephan Mielke
Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute NHLBI, National Institutes of Health NIH, Bethesda, MD 20892 1202, USA
Blood 110:1689-97. 2007.... - Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemiaElena E Solomou
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
Blood 110:1603-6. 2007..Our findings indicate that decreased NFAT1 could explain low FOXP3 expression and diminished Treg frequency in aplastic anemia. Treg defects are now implicated in autoimmune marrow failure... - High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effectsAgnes S M Yong
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
Blood 110:770-5. 2007..The presence of a donor immune response against PR1 may be advantageous and could be exploited therapeutically... - Neutrophil granule proteins as targets of leukemia-specific immune responsesJohn Barrett
Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
Curr Opin Hematol 13:15-20. 2006..Frequencies are higher in patients with myeloid leukemias, and highest in patients with chronic myeloid leukemia entering molecular remission after allogeneic stem cell transplantation... - Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemiasA J Barrett
Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
Clin Exp Immunol 148:189-98. 2007..These promising early results point the way to optimizing the administration of peptide vaccines and suggest ways of combining vaccination with allogeneic stem cell transplantation to boost GVL effects... - Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastaseHiroshi Fujiwara
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
Blood 103:3076-83. 2004..HNE could, therefore, be used in an HLA-unrestricted manner to induce leukemia-reactive CTLs for adoptive immunotherapy... - In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteinsHiroshi Fujiwara
Stem Cell Allotransplant Section, Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 11:4495-503. 2005..This study emphasizes the clinical potential of PGP for expansion and adoptive transfer of polyclonal leukemia antigen-specific T cells to treat leukemia... - A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion techniqueStephan Mielke
Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
Blood 111:4392-402. 2008..This procedure is currently being investigated in a clinical trial of allotransplantation... - G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyteGiuseppe Sconocchia
Hematopoietic Stem Cell Transplantation Section, National Heart Lung and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda MD 20892 0001, USA
J Leukoc Biol 76:1214-9. 2004..The generation of CD56+ cells was negatively regulated by hyaluronic acid and IL-4, indicating that extracellular matrix may play an important role in the commitment of CD34+ cells into CD56 myeloid and lymphoid lineages... - Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantationBipin N Savani
Hematology Branch, National Heart, Lung and Blood, National Institutes of Health, Bethesda, Maryland 20892-1202, USA
Biol Blood Marrow Transplant 12:1261-9. 2006..Longer follow-up is needed to determine whether PF will continue to decrease or reach a plateau and whether more patients with PF abnormality will eventually become symptomatic... - Phenotype and function of a CD56+ peripheral blood monocyteG Sconocchia
Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Leukemia 19:69-76. 2005..These results define a minor monocyte population with distinct phenotypic and functional features... - Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastaseFrank El-Ouriaghli
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
Blood 102:3786-92. 2003..These results suggest that elastase overproduction by the leukemic clone can change the growth environment by digesting growth factors, thereby giving advantage to Ph+ hematopoiesis... - The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactionsGiuseppe Sconocchia
Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung and Blood Institute, Department of Transfusion Medicine, Clinical Center, National Institutes of Health (NIH, Bethesda, MD 20892, USA
Blood 106:3666-72. 2005..However, in vivo, CML cells may avoid NK-cell-mediated immune destruction by immune escape, shedding MICA into the plasma, thereby down-regulating NKG2D on CML CD56(+) cells... - Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantationBipin N Savani
Hematology Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA
Biol Blood Marrow Transplant 13:1216-23. 2007..These results indicate that LC30 is a surrogate for robust engraftment and identifies an "at-risk" population of patients after T cell-depleted SCT... - Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantationKatayoun Rezvani
Department of Haematology, 4th Floor Commonwealth Building, Hammersmith Hospital, DuCane Road, London W12 0NN, UK
Best Pract Res Clin Haematol 21:437-53. 2008..Finally, these approaches to increase GvL effects would be facilitated by transplant approaches to deplete GvHD alloresponses selectively while preserving GvL reactivity... - CD8+ T cells reactive to survivin antigen in patients with multiple myelomaMatthias Grube
Department of Hematology and Oncology, Institute of Pathology, University of Regensburg, Regensburg, Germany
Clin Cancer Res 13:1053-60. 2007..We did this study to investigate whether survivin-specific CD8+ T cells occur in patients with multiple myeloma... - PR1 vaccination in myeloid malignanciesKatayoun Rezvani
Haematology Department, Imperial College, London, UK
Expert Rev Vaccines 7:867-75. 2008..These promising early results point the way to optimizing the administration of peptide vaccines to improve the treatment of otherwise refractory myeloid leukemias...